[go: up one dir, main page]

WO2012008733A3 - Stem cells derived from primary placenta tissue and cellular therapeutic agent containing same - Google Patents

Stem cells derived from primary placenta tissue and cellular therapeutic agent containing same Download PDF

Info

Publication number
WO2012008733A3
WO2012008733A3 PCT/KR2011/005103 KR2011005103W WO2012008733A3 WO 2012008733 A3 WO2012008733 A3 WO 2012008733A3 KR 2011005103 W KR2011005103 W KR 2011005103W WO 2012008733 A3 WO2012008733 A3 WO 2012008733A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
cells derived
placenta tissue
therapeutic agent
cellular therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/005103
Other languages
French (fr)
Korean (ko)
Other versions
WO2012008733A2 (en
Inventor
임진호
이영재
박세영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MARIA BIOTECH
Original Assignee
MARIA BIOTECH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MARIA BIOTECH filed Critical MARIA BIOTECH
Publication of WO2012008733A2 publication Critical patent/WO2012008733A2/en
Publication of WO2012008733A3 publication Critical patent/WO2012008733A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to stem cells derived from primary placenta tissue at 14 weeks or less of gestation, to a method for separation of same, to a method for proliferation of same, and to a cellular therapeutic agent containing the stem cells. More particularly, the present invention relates to stem cells derived from primary placenta tissue at 14 weeks or less of gestation, to a method for separation of same, to a method for proliferation of same, and to a cellular therapeutic agent containing the stem cells, wherein the stem cells: (a) exhibit positive immunological properties with respect to CD9, CD13, CD29, CD44, CD90, CD105 and HLA-class I, and negative immunological properties against CD14, CD19, CD34, CD38, CD45, CD127 and HLA-DR; (b) express genes of Oct4, Nanog, Tbn, Klf4, Activin and Rex1; (c) have the ability of differentiation into cells derived from an ectoderm, mesoderm, or endoderm; and are maintained for 30 generations or more in an undifferentiated state. In spite of being adult stem cells, adult stem cells derived from placenta tissue according to the present invention have excellent cell proliferation and advantageous differentiation ability compared to existing stem cells derived from placenta tissue, and thus can be efficiently used as a cellular therapeutic agent. In particular, the stem cells have the ability to differentiate into nerve cells, bone-forming cells, or pancreatic beta cells that secrete insulin, and are also efficient at treating bone defect diseases, nerve diseases, diabetes, etc.
PCT/KR2011/005103 2010-07-12 2011-07-12 Stem cells derived from primary placenta tissue and cellular therapeutic agent containing same Ceased WO2012008733A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100067086A KR20120006386A (en) 2010-07-12 2010-07-12 First placental tissue-derived stem cells and cell therapy containing the same
KR10-2010-0067086 2010-07-12

Publications (2)

Publication Number Publication Date
WO2012008733A2 WO2012008733A2 (en) 2012-01-19
WO2012008733A3 true WO2012008733A3 (en) 2012-04-19

Family

ID=45469910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/005103 Ceased WO2012008733A2 (en) 2010-07-12 2011-07-12 Stem cells derived from primary placenta tissue and cellular therapeutic agent containing same

Country Status (2)

Country Link
KR (1) KR20120006386A (en)
WO (1) WO2012008733A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2747951T3 (en) 2013-10-24 2020-03-12 Ospedale San Raffaele Srl Method
JP6545690B2 (en) * 2014-01-08 2019-07-17 サムスン ライフ パブリック ウェルフェア ファウンデーション Stem cells derived from trophoblast basal layer and cell therapeutic agent containing the same
ES2870567T3 (en) 2014-01-08 2021-10-27 Samsung Life Public Welfare Foundation Stem cells from a pure chorionic trophoblastic layer and cell therapy comprising the same
KR102413235B1 (en) * 2017-12-22 2022-06-24 고려대학교 산학협력단 Placenta-derived cells conditioned media for inducing de-differentiation from somatic cell into induced pluripotent stem cell and method for inducing de-differentiation using the same
WO2020036245A1 (en) * 2018-08-17 2020-02-20 고려대학교 산학협력단 Placenta-derived cell conditioned medium for production and function enhancement of human neural stem cells, and use therefor
KR102317052B1 (en) * 2020-05-04 2021-10-25 주식회사 티에스셀바이오 Composition derived from placenta showing anti-inflammation and anti-viral effect

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BATTULA ET AL.: "Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation", DIFFERENTIATION, vol. 75, 2007, pages 279 - 291, XP026765256, DOI: doi:10.1111/j.1432-0436.2006.00139.x *
MIAO ET AL.: "Isoration of mesenchymal stem cells from human placenta: Comparison with human bone marrow mesenchymal stem cells", CELL BIOLOGY INTERNATIONAL, vol. 30, 2006, pages 681 - 687 *
PORTMANN-LANZ ET AL.: "Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration", AMERICAN, vol. 194, 2006, pages 664 - 673 *

Also Published As

Publication number Publication date
WO2012008733A2 (en) 2012-01-19
KR20120006386A (en) 2012-01-18

Similar Documents

Publication Publication Date Title
Kim et al. Human chorionic-plate-derived mesenchymal stem cells and Wharton’s jelly-derived mesenchymal stem cells: a comparative analysis of their potential as placenta-derived stem cells
Vallone et al. Mesenchymal stem cells and their use in therapy: what has been achieved?
Patel et al. Multipotent menstrual blood stromal stem cells: isolation, characterization, and differentiation
Vellasamy et al. Isolation and characterisation of mesenchymal stem cells derived from human placenta tissue
WO2012008733A3 (en) Stem cells derived from primary placenta tissue and cellular therapeutic agent containing same
EP2550356A4 (en) Method of altering the differentiative state of a cell and compositions thereof
Jaramillo‐Ferrada et al. Differential mesengenic potential and expression of stem cell‐fate modulators in mesenchymal stromal cells from human‐term placenta and bone marrow
Vishnubalaji et al. Skin-derived multipotent stromal cells–an archrival for mesenchymal stem cells
NZ594848A (en) Use of adipose tissue-derived stromal stem cells in treating fistula
WO2012040465A3 (en) Multipotent stem cells and uses thereof
Jiao et al. Human mesenchymal stem cells derived from limb bud can differentiate into all three embryonic germ layers lineages
MX2019003936A (en) A method of isolating mesenchymal stem cells from umbilical cord amniotic membrane using a cell culture medium.
Kmiecik et al. Fetal membranes as a source of stem cells
EP2155860A4 (en) MULTIPOTENT STEM CELLS AND USES THEREOF
WO2009136283A3 (en) Multipotent adult stem cell population
WO2008084401A3 (en) Composition and method for enabling proliferation of pluripotent stem cells
Wang et al. Characterization and therapeutic application of mesenchymal stem cells with neuromesodermal origin from human pluripotent stem cells
RU2014129756A (en) INDUCED PLURIPOTENT STEM CELLS FROM CELLS OBTAINED FROM HUMAN CUISINE TISSUE
WO2013015644A1 (en) Method for proliferating placenta-derived stem cells
Iacono et al. Stem cells from foetal adnexa and fluid in domestic animals: an update on their features and clinical application
A. Somoza et al. Cell therapy using induced pluripotent stem cells or somatic stem cells: this is the question
Hua et al. Multipotent mesenchymal stem cells (MSCs) from human umbilical cord: potential differentiation of germ cells
WO2011024070A3 (en) Composition and method for proliferating undifferentiated stem cells
Ramasamy et al. Stem cells derived from amniotic fluid: a potential pluripotent-like cell source for cellular therapy?
Hatzfeld et al. A sub-population of high proliferative potential-quiescent human mesenchymal stem cells is under the reversible control of interferon α/β

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11807018

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11807018

Country of ref document: EP

Kind code of ref document: A2